Skip to main content

Table 3 Bivariate Analysis Association between Comorbidities and NAFLD

From: The role of Small Intestinal Bacterial Overgrowth (SIBO) in Non-alcoholic Fatty Liver Disease (NAFLD) patients evaluated using Controlled Attenuation Parameter (CAP) Transient Elastography (TE): a tertiary referral center experience

Variables NAFLD, n (%) Total p value PR CI 95%
Yes No
DM, n (%)
 Yes 85 (70.8) 35 (29.2) 120 (100) 0.612 0.810 0.358–1.832
 No 30 (75.0) 10 (25.0) 40 (100)    
Dyslipidemia, n (%)
 Yes 97 (75.2) 32 (24.8) 129 (100) 0.057 2.189 0.966–4.959
 No 18 (58.1) 13 (41.9) 31 (100)    
Obesity, n (%)
 Yes 82 (76.6) 25 (23.4) 107 (100) 0.057 1.988 0.974–4.057
 No 33 (62.3) 20 (37.7) 53 (100)    
Metabolic Syndrome, n (%)
 Yes 89 (73) 33 (27) 122 (100) 0.588 1.245 0.564–2.748
 No 26 (68.4) 12 (31.6) 38 (100)    
Central Obesity, n (%)
 Yes 109 (73.2) 40 (26.8) 149 (100) 0.294 2.271 0.657–7.854
 No 6 (54.5) 5 (45.5) 11 (100)    
  1. DM Diabetes Mellitus, NAFLD Non-Alcoholic Fatty Liver Disease, PR Prevalence Ratio, CI Confidence Interval